Kirin Holdings reported that annual sales of products and materials containing its LC-Plasma strain exceeded ¥28 billion in 2025.
The Japan FMCG brand said stronger year-round demand for immune support helped drive performance across supplements, beverages and dairy.
Internal data covering January to December 2025 showed broad-based growth.
The iMUSE supplement series increased around 30% year on year. The W-Care range, positioned around sleep and visceral fat management, expanded by roughly 80%.
Beverages containing LC-Plasma rose about 10% overall. Chilled formats under the Oishii Immune Care line grew approximately 40%, supported by seasonal promotions and wider distribution.
Yogurt sales also advanced. The Koiwai Immune Care Yogurt brand increased around 10%, while the 400g Light Sweetness variant rose about 40% compared with the previous year.
Overseas shipments of LC-Plasma as a raw material climbed approximately 50%. New product launches in Taiwan and China, alongside a sales-commission agreement targeting Europe and the Americas, supported international expansion.
By the end of 2025, 12 partner companies were marketing 24 functional food products containing LC-Plasma. New additions included dual-benefit tablets combining bone density and immune positioning.
Kirin linked the overall performance to sustained consumer focus on daily health management rather than winter-only demand.
LC-Plasma remains a central component of Kirin’s Health Science portfolio as the group continues expanding its functional food presence globally.
